Context Penile cancer is a rare disease but has a significant impact on quality of life. Its incidence
is increasing, so it is important to include new and relevant evidence in clinical practice …

… Financial disclosures: Michiel S. van der Heijden certifies that all conflicts of interest, including
… MS van der Heijden: consultancy fees (to institute)—AstraZeneca/Medimmune, Roche/…

Context Lymph node (LN) involvement in penile cancer is associated with poor survival.
Early diagnosis and management significantly impact survival, with multimodal treatment …

Background Survival outcomes are poor for patients with metastatic urothelial carcinoma
who receive standard, first-line, platinum-based chemotherapy. We assessed the overall …

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival, …

Background Patients with metastatic urothelial carcinoma have few treatment options after
failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab…

Background Few options exist for patients with locally advanced or metastatic urothelial
carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety …

Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-ligand
1 (PD-L1) pathway can induce robust and durable responses in patients with various …

Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on
genomic alterations but have rarely considered the biological properties of plasma cell-free …

… Michiel S. van der Heijden: consulting or advisory role: Roche/Genentech, Astellas Pharma,
AstraZeneca/MedImmune; travel, accommodations, expenses: Novartis, Astellas Pharma, …